# Problem Context
You are given structured information describing a scientific research problem.

## Problem Description
[예시 문제5]  T 세포 탈진 억제 약물 재활용(drug repositioning) 후보 예측
T 세포 탈진(exhaustion)은 만성 감염, 종양 미세환경에서 반복 자극을 받은 T 세포가 기능을 상실하는 현상으로, 면역항암제의 반응성 저하와 치료 실패의 중요한 원인이다. 탈진을 역전시키는 약물 또는 조합을 발굴하는 것은 면역치료 혁신의 핵심 과제로 여겨진다.
본 문제의 목표는 공개된 약물–유전자·전사체 데이터베이스를 통합하여, T 세포 탈진 유전자 시그니처를 역전(reversal)시킬 수 있는 약물 후보를 예측하고 그 근거를 제시하는 것이다.


입력 데이터 Q5
* exhaustion_signature → T 세포 탈진 관련 상향/하향 조절 유전자 목록
아래는  Drug-related Open Data 를 참고할 것
* 약물–표적 단백질/유전자 연결 정보
* 이미 임상·전임상에서 사용되거나 연구 중인 약물 정보


아래 요구사항을 충족하는 분석 전략을 제시하라.


핵심 포인트:
* 약물–표적 네트워크 이해
* 탈진 시그니처를 기반으로 한 signature reversal 접근 실습
* 약물 우선순위화 및 작용 기전 가설 도출


(A) T 세포 탈진 시그니처 분석
(B) 약물–유전자 네트워크 기반 후보 탐색
(C) 약물 후보 선정 및 기전 가설 제시

## Core Objective
Design an integrated analysis strategy to predict drug repositioning candidates that can reverse T cell exhaustion by integrating T cell exhaustion gene signatures with drug–target and drug–transcriptomic open databases, and to propose mechanistic hypotheses for prioritized drugs.

# Task Details


## Suggested Direction


---

# Task
Using the information above, generate a structured scientific report that addresses the stated problem by synthesizing relevant prior research.


[List of Sub-Problems to Address]
- [SINGLE] Integrated Strategy for Drug Repositioning to Reverse T Cell Exhaustion
  Description: Propose a comprehensive analysis strategy that (A) characterizes the T cell exhaustion gene signature, (B) identifies candidate drugs using drug–gene/target network and signature reversal concepts, and (C) prioritizes drugs and formulates plausible mechanisms of action explaining how they may alleviate T cell exhaustion. All three components should be addressed as one coherent workflow.
  Approach: 1) Analyze the exhaustion_signature by separating up- and down-regulated genes, performing functional enrichment (e.g., GO, KEGG, Reactome) to identify exhausted T cell pathways (inhibitory receptors, metabolic dysregulation, epigenetic control). 2) Apply a signature reversal framework by mapping the exhaustion signature onto drug-induced gene expression or drug–target networks; prioritize drugs whose targets inhibit up-regulated exhaustion drivers or activate down-regulated effector/memory pathways. Network-based approaches (drug–target–pathway networks, network proximity, or random-walk-based scoring) should be emphasized. 3) Rank drug candidates based on reversal score, network centrality, clinical status (approved/preclinical), and immune relevance, then generate mechanistic hypotheses linking each drug’s targets to known T cell exhaustion biology (e.g., checkpoint signaling, metabolic reprogramming, transcriptional regulators).

